Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Kedrab Market Size, Value And Growth Trajectory Through 2030
The expansion observed historically was due to elevated rabies death rates, the dependence on immunoglobulin preparations, restricted prompt vaccine availability, established public health emergency guidelines, and inpatient rabies care.
Projected expansion during the forecast period is driven by a rise in animal bite occurrences, the proliferation of rabies awareness initiatives, an increase in emergency medical facilities, enhanced availability of monoclonal antibodies, and increased governmental funding for rabies control.
Noteworthy patterns for the upcoming period involve the growing adoption of rabies passive immunization techniques, the broadening of post-exposure prophylaxis programs, a heightened emphasis on managing zoonotic diseases, greater demand for emergency immunotherapy, and the reinforcement of public health response frameworks.
Get A Free Sample Report With In-Depth Market Insights:
Kedrab Market Industry Drivers: What’s Behind The Revenue Growth?
The rising occurrence of rabies is anticipated to propel the kedrab market in the future. Rabies, an almost uniformly deadly illness resulting from encounters with infected animals, presents a significant public health issue, especially where vaccine availability is poor. This growing incidence of rabies stems from insufficient immunization of pets, restricted availability of post-exposure treatment, and the widespread presence of rabies in wild animals, particularly in areas lacking sufficient resources. Kedrab is a human rabies immunoglobulin employed to provide immediate, passive immunity to individuals exposed to the rabies virus, offering vital safeguarding until active immunity is established via vaccination. For example, in April 2024, the South Dakota Department of Health, a US-based government agency, reported that approximately 20 animals in South Dakota were confirmed to have rabies in 2023. This represented a 122% rise compared to the 9 cases documented in 2022. Consequently, the increasing frequency of rabies cases fuels the kedrab market.
Kedrab Market Segmentation: How Does The Market Break Down By Category?
The kedrab market covered in this report is segmented –
1) By Indication: Post-Exposure Prophylaxis For Rabies, Treatment For Patients Exposed To Suspected Rabid Animals
2) By Formulation: Injectable Formulation, Lyophilized Powder For Reconstitution
3) By Route Of Administration: Intramuscular Injection, Subcutaneous Injection
4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Emergency Departments, Specialty Clinics, Public Health Organizations
#Kedrab Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies in the kedrab market are focused on developing innovative solutions and obtaining regulatory clearances, such as exclusive licensing and distribution continuation notices, to boost kedrab’s commercial reach and market presence in the U.S. An exclusive licensing and distribution continuation notice serves as an official announcement from a pharmaceutical or biotechnology company, signifying the extension or renewal of an existing agreement that grants exclusive rights to license, distribute, or commercialize a specific product. For instance, in July 2023, Kamada Ltd., an Israel-based plasma-derived biopharmaceutical company, disclosed that Kedrion Biopharma exercised its option to extend the exclusive U.S. distribution agreement for KEDRAB, a human rabies immune globulin utilized for post-exposure prophylaxis. KEDRAB delivers immediate passive immunity against rabies following potential exposure, having demonstrated efficacy, safety, and regulatory approval in the U.S. The two-year extension guarantees sustained availability and supply stability, thereby strengthening Kedrion’s commercial distribution infrastructure and strategic position within the U.S. immunoglobulin market, which in turn enhances patient access and public health preparedness.
Kedrab Market Competitive Overview And Top Companies
Major companies operating in the kedrab market are Kamada Ltd., Kedrion Biopharma Inc.
View The Full Kedrab Market Report:
Kedrab Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the kedrab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kedrab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
